One good one, deserves another!
In a recent, but expected development, the SEC has moved forward and filed a damning a case against DECN, seeking financial damages, for among other things, their documented misleading PRs and claims. The investigation found that despite company's continued discussion of "progress", the company still had not filed a single EUA. The lack of a prototype, even as late as the follow up SEC filing in the suspension case, was also cited as a key factor.
The SEC, as well as the Administration, stressed at how every American should feel insulted and outraged that this company used this pandemic as a way to draw interest to the company, benefiting through the selling of additional shares, allowing the company to continue, undaunted with implications and claims that their tests even came close to FDA standards.
The SEC has also gone onto say that other findings against the company will be made public soon.
News 
Market Data 
Discover 
AI
